Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference

On September 22, 2022 Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, reported that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation and participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:30 p.m. ET in New York, New York (Press release, Aileron Therapeutics, SEP 22, 2022, View Source [SID1234621343]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation and fireside chat will be available under the Investors & Media section of the company’s website at aileronrx.com. A replay of the webcast will be archived on the Aileron website for approximately 30 days following the presentation.

Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit

On September 22, 2022 Abeona Therapeutics Inc. (Nasdaq: ABEO) reported that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 8:30 a.m. ET (Press release, Abeona Therapeutics, SEP 22, 2022, View Source [SID1234621342]). The Company will also participate in one-on-one investor meetings at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the Investors section of the Abeona website under "Events" at View Source The webcast will be archived for 30 days. Those interested in attending the fireside chat or requesting a one-on-one meeting with Abeona are encouraged to contact their Jefferies representative.

Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference

On September 22, 2022 Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, reported that the company will participate in the investor-focused Cantor Oncology & HemOnc Conference on September 28, 2022 (Press release, Akari Therapeutics, SEP 22, 2022, View Source [SID1234621340]). President and CEO Rachelle Jacques will take part in a conference panel, Addressing Challenges in Cell Therapy and Transplant, at 9:00 a.m. Eastern time and will attend 1:1 investor meetings.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Arbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference

On September 22, 2022 Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, reported that the Company will participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference taking place in New York on Tuesday, October 4, 2022 at 2:30 pm ET (Press release, Arbutus Biopharma, SEP 22, 2022, View Source [SID1234621339]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presenters: William Collier, President & Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Offer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer

A live webcast of the fireside chat can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com. An archived replay of the webcast will be available on the Arbutus website after the event.

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

On September 22, 2022 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, reported the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-6291, an oral, selective, covalent KRASG12C(ON) Inhibitor designed to treat patients with cancers driven by the KRASG12C mutation (Press release, Revolution Medicines, SEP 22, 2022, View Source [SID1234621338]). RMC-6291, which exhibits a potential best-in-class preclinical profile, is the first drug candidate from the company’s pipeline of mutant-selective RAS(ON) Inhibitors to enter the clinic. Last quarter, Revolution Medicines initiated clinical development of RMC-6236, its oral RASMULTI(ON) Inhibitor designed to treat patients with cancers driven by a variety of RAS mutations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1/1b trial (NCT05462717) sponsored by Revolution Medicines is a multicenter, open-label, dose-escalation and dose-expansion study of RMC-6291 in patients with advanced solid tumors harboring the KRASG12C mutation. The primary objectives of the study are to evaluate safety and tolerability and to inform the recommended Phase 2 dose and schedule (RP2DS) for the compound.

"RMC-6291 is an exciting first drug candidate from our collection of oral, mutant-selective RAS(ON) Inhibitors to advance into clinical development, and we expect learnings from this trial will also inform advancement of our pipeline of innovative compounds. The next mutant-selective RAS(ON) inhibitor we plan to advance into the clinic is RMC-9805, an oral and covalent inhibitor of KRASG12D, the most common mutant RAS driver of human cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "The mutant-selective approach exemplified by RMC-6291, RMC-9805 and other assets in our pipeline differs from the profile of RMC-6236, which entered clinical evaluation recently and is designed to inhibit many RAS variants rather than a single RAS mutation. We believe that these complementary approaches, used in monotherapy and/or combination treatment regimens, will provide a powerful set of tools for countering the complex processes that cause and sustain a wide range of RAS-addicted cancers."